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use of single-use equipment rather than reusable equip-
ment also increases the variable unit costs significantly.
SESSION II
HEALTH POLICY II
HP4
PRICING OF PHARMACEUTICALS IN CANADA 
AND EUROPE: A COMPARATIVE ANALYSIS
Palmer WN
Palmer D’Angelo Consulting Inc, Ottawa, ON, Canada
OBJECTIVES: This paper compares pricing and reim-
bursement of pharmaceuticals between Canada and se-
lected European countries.
METHODS: We examined the pricing and reimburse-
ment schemes and cost-containment initiatives adopted
in Europe and Canada and their impact on prices of ex-
isting and new medications. Published data from the Pat-
ented Medicine Prices Review Board (PMPRB) provides
international price comparisons for patented medicines
available in Canada. Prices for 13 new active substances
first marketed in Canada in 2000 were assembled for
Canada and six European countries. For comparative
purposes, prices in the United States were also included in
the analysis.
RESULTS: Drug prices in Canada are typically lower
than prices in Germany, Sweden, Switzerland, and the
UK but higher than prices in France and Italy. Patented
Drugs were 8% lower than the international median as
measured by the PMPRB. However, for new drugs intro-
duced in 2000, prices were, on average, 8.3% higher than
those in Europe, although most were within the range of
European prices. Prices in Canada and Europe were al-
most always lower than those in the United States.
CONCLUSIONS: The health-care systems in Canada
and Europe are fairly similar, as are the drug pricing and
reimbursement schemes. However, local policies (e.g.,
reference pricing, generic substitution, pharmacoeconom-
ics) can result in significant international price variations
and the potential for parallel importation. Cost-effective-
ness and international price comparisons play an impor-
tant role in most major markets. The prices of pharma-
ceuticals in Canada are comparable to those in Europe
although there is a trend for Canadian prices to be
higher. Although pharmaceutical prices in Canada and
Europe appear to be lower than in the United States,
there are important differences in the health-care systems
as well as in the reimbursement mechanisms that make
price comparisons with the US problematic.
HP5
USE OF THE SOJA METHOD FOR CHOOSING A 
HMG CO-A REDUCTASE INHIBITOR (STATIN)
IN IRELAND
Heerey A, McGowan B, Barry M
National Centre for Pharmacoeconomics, Dublin, Ireland
OBJECTIVE: The System of Objectified Judgement
Analysis (SOJA) method is a recognized, standardized
system, which aims to distinguish a medication of choice
from a class of drugs. It combines expert opinion on pri-
orities during prescription, with clinical evidence per in-
dividual drug. We used the SOJA method in the Irish set-
ting for statins and compared the results to their actual
prescribing patterns in Ireland.
METHODS: A questionnaire was sent to 1,705 Irish gen-
eral practitioners (GPs) asking them to rank between 0
and 10 the relative importance of 11 criteria when pre-
scribing statins. These average results were assigned to
the SOJA method. The higher the overall SOJA score per
medication, the better the statin performed and the more
evidence to support the prescription of this drug over
others in the same class. The SOJA results were com-
pared to the number of statin prescriptions for public pa-
tients at the time the questionnaire was completed (Aug/
Sept 2000).
RESULTS: There was a 42% reply rate. The average or-
der of importance, as rated by the GPs were clinical effi-
cacy (9.26), side effects (8.24), drug interactions (7.93),
dosage frequency (7.53), clinical endpoint studies (7.50),
number of approved indications (7.07), documentation
(6.96), cost-effectiveness (6.95), bioavailablility (6.69),
absorption (6.46) and number of formulations (5.55).
The resulting SOJA score (with number of prescriptions)
were simvastatin 64.6 (7,150), atorvastatin 59.5 (19,770),
pravastatin 59.4 (34,736), cerivastatin 56.3 (3,500) and
fluvastatin 51.4 (4,134).
CONCLUSION: This study indicated that simvastatin
should be the statin of choice in Ireland followed by ator-
vastatin or pravastatin. However, pravastatin is by far
the most widely prescribed statin. This suggests that non-
rationale factors such as marketing may be influencing
prescribing in Ireland. Additionally, despite the fact that
statins represent one of the most expensive long-term
therapies, Irish GPs rank cost-effectiveness low on the list
of priorities during their prescription.
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THE IMPACT OF PIPELINE DRUGS ON 
UNITED STATES DRUG EXPENDITURE
GROWTH TRENDS
Mullins CD, Wang J, Palumbo FB, Stuart B
University of Maryland, Baltimore, MD, USA
OBJECTIVE: Our study had two objectives. The first
was to disaggregate historical drug expenditure increases
into three components: price increase, utilization in-
crease, and product shift. The second objective was to
demonstrate the potential impact of pipeline drugs on an-
nual drug-expenditure increases, factoring in what has
been observed historically for newer drugs.
METHODS: The method for calculating pure price infla-
tion involved a fixed set of drugs and measured the utili-
zation-weighted mean of annual percentage increases.
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The calculation of utilization increases reflects the change
in the aggregate number of prescriptions filled. The cal-
culation of annual increase in expenditures reflects the
change in expenditure from an old set of drugs to a new
set. To estimate the impact of pipeline drugs, case scenar-
ios were performed around HCFA’s baseline projections
for future drug trends. The compounded, annual, growth-
rate decrease of new drug approvals was used as a lower
bound, while a constant increase in the pipeline projection
provided the upper bound.
RESULTS: Historically, slightly less than one-third of the
increase in drug expenditure was due to price increases
on existing drugs, approximately one-third was due to in-
creases in the utilization of existing drugs, and slightly
more than one-third was due to product shift. Based on
our data, the historical increase in expenditures was 15%
for all drugs, 25% for newer drugs and 7% for older
drugs. Our lower and upper bound scenarios projected
national drug expenditures of $191.56 billion and
$215.62 billion, respectively, for 2004.
CONCLUSION: The impact of pipeline drugs on future
drug trends is significant. There is considerable variation
surrounding the impact of pipeline drugs on future drug
expenditures based on several plausible scenarios.
CANCER II
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THE IMPACT OF THE DIAGNOSIS OF CANCER 
ON OUT-OF-POCKET HEALTH-CARE 
EXPENDITURES MADE BY THE US ELDERLY
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Fendrick AM1
1University of Michigan, Ann Arbor, MI, USA; 2Ortho Biotech, 
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If the “total” costs of a disease, such as cancer, are to be
accurately quantified, out-of-pocket expenditures (OOPE)
made by patients and caregivers must be added to costs
incurred by third party payers (direct medical) and em-
ployers (lost productivity). Prior studies of OOPE by the
elderly used small geographically restricted samples and
narrow patient subgroups.
OBJECTIVES: To rigorously quantify OOPE for individ-
uals older than 70 years in the United States. To empha-
size cancer-related OOPE, three patient cohorts were ex-
amined: 1) no cancer (No CA); 2) history of cancer but
not undergoing treatment (CA/No Tx), and 3) undergo-
ing active cancer treatment (CA/Tx).
METHODS: Data from the Asset and Health Dynamics
Study, a nationally representative, longitudinal survey of
community-dwelling elderly were used. Respondents de-
noted cancer status and reported OOPE over two years
for: 1) nursing home/hospitals; 2) doctor visits; 3) pre-
scription drugs, and 4) “special” services. Using a multi-
variable two-part regression model to control for differ-
ences in co-morbidity, health status, living situation, and
sociodemographics, the additional cancer-related OOPE
was estimated.
RESULTS: Of the 6576 respondents, 5553 (84%) re-
ported No CA, 843 (13%) reported CA/No Tx, and 180
(3%) reported CA/Tx. Cancer diagnosis and current can-
cer treatment were significant predictors of increased
OOPE compared to no cancer. The mean annual OOPE
for No CA, CA/No Tx, and CA/Tx groups was US$1900,
US$2400, and US$3300, respectively (p  .001). Hospi-
tals (US$1400/yr) and prescription drugs (US$1100/yr)
were the largest OOPE components for the CA/Tx group.
The incremental OOPE for CA/No Tx and CA/Tx pa-
tients approximates US$1.5 billion annually.
CONCLUSIONS: OOPE for elderly individuals with a
history of cancer or ongoing therapy are substantial and
significantly greater than for those without cancer. If
OOPE remain unaccounted for, total costs of cancer will
be consistently underestimated. Economic evaluations of
interventions aimed at cancer prevention and treatment
must account for OOPE.
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A SPECIFIC QUALITY OF LIFE SCALE IN
UPPER LIMB LYMPHOEDEMA: THE
ULL-27 QUESTIONNAIRE
Launois R1, Mègnigbêto A1, Le Lay K1, Alliot F2
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OBJECTIVE: The aim of this study was to validate a self-
completed questionnaire in Upper Limb Lymphoedema.
METHODS: A qualitative survey was conducted to iden-
tify patients’ complaints. This questionnaire was admin-
istered to 154 patients. Principal component analysis was
used to identify dimensions. A validation study was con-
ducted in 304 patients. Six instruments have been used in
the case report form: volume differences between the
healthy and the affected arms; composite symptom scales
completed by clinicians from patient interviews; ULL-27
and SF-36 scales completed by patients; overall opinion
of doctors and patients. Internal validity was checked
through factorial analysis. Trait validity was investigated
by correlating the domains rated with ULL-27 with the
SF-36 scale. Nomologic validity was tested by comparing
the means of the ULL-27 subscales across severity stages.
Sensitivity was tested only in patients with progressive
disease between D0 and D28 by comparing mean sub-scores
for the ULL-27 scale and by calculating the effect size.
RESULTS: Three hundred four patients were included in
the study. Factorial analysis isolated three dimensions:
physical (15 items), psychological (7 items), and social
withdrawal (5 items). The Cronbach coefficients are
greater than 0.80 for all dimensions. The Spearman cor-
relations clearly distinguish the different life domains
from each other. At D0 the physical and social dimen-
sions of ULL-27 scale were significantly correlated with
severity of illness but it was not the case for the psycho-
